title: Type III Hyperlipoproteinemia: Still Worth Considering?
abstract: Familial type III hyperlipoproteinemia (HLP) was first recognized as a distinct entity over 60 years ago. Since then, it has proven to be instructive in identifying the key role of apolipoprotein E (apoE) in removal of the remnants of very low density lipoproteins and chylomicrons produced by the action of lipoprotein lipase on these triglyceride-transporting lipoproteins. It has additionally shed light on the potent atherogenicity of the remnant lipoproteins. This review describes the history of development of our understanding of type III HLP, discusses the several genetic variants of apoE that play roles in the genesis of type III HLP, and describes the remarkable responsiveness of this fascinating disorder to lifestyle modification, especially carbohydrate restriction and calorie restriction, and, when required, the addition of pharmacotherapy.
authors.affiliation: Columbia University College of Physicians and Surgeons, New York, NY 10019, USA. Electronic address: cbb1@cumc.columbia.edu.
authors.forename: Conrad B
authors.initials: CB
authors.lastname: Blum
mesh_terms: D001057:Apolipoproteins E / Q000378:metabolism; D019468:Disease Management; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000235:genetics / Q000523:psychology / Q000628:therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D040242:Risk Reduction Behavior
chemical_list: D001057:Apolipoproteins E; D000960:Hypolipidemic Agents
keywords: Apolipoprotein E; Dysbetalipoproteinemia; Remnant lipoproteins; Type III hyperlipoproteinemia